APO Research
Talk to an analyst

APO RESEARCH · REPORT

Attenuated Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Attenuated Vaccine Market Analysis and Forecast 2026-2032

30 December 2025190 pages

Choose your research edition.

Industry ResearchAttenuated Vaccine Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Attenuated Vaccine Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Attenuated Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Attenuated Vaccine Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Attenuated Vaccine Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Attenuated Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Attenuated Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Attenuated Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Attenuated Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Attenuated Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Attenuated Vaccine include Changchun BCHT Biotechnology Co.,Ltd, Shanghai Rongsheng Biotech, Sanofi, Johnson & Johnson, Merck & Co., Pfizer Inc, GlaxoSmithKline plc, Serum Institute of India Pvt. Ltd. and Green Cross Corporation, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Attenuated Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Attenuated Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Attenuated Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Attenuated Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Attenuated Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Attenuated Vaccine sales, projected growth trends, production technology, application and end-user industry.

Attenuated Vaccine Segment by Company

Changchun BCHT Biotechnology Co.,Ltd

Shanghai Rongsheng Biotech

Sanofi

Johnson & Johnson

Merck & Co.

Pfizer Inc

GlaxoSmithKline plc

Serum Institute of India Pvt. Ltd.

Green Cross Corporation

CSL Limited

Biken

Astellas Pharma

Attenuated Vaccine Segment by Type

Bacterial Vaccine

Viral Vaccine

Attenuated Vaccine Segment by Application

Hospital

Clinic

Others

Attenuated Vaccine Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Attenuated Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Attenuated Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Attenuated Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Attenuated Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Attenuated Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Attenuated Vaccine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Attenuated Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Bacterial Vaccine Major Manufacturers Table 3. Viral Vaccine Major Manufacturers Table 4. Global Attenuated Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospital Major Manufacturers Table 6. Clinic Major Manufacturers Table 7. Others Major Manufacturers Table 8. Attenuated Vaccine Industry Trends Table 9. Attenuated Vaccine Industry Drivers Table 10. Attenuated Vaccine Industry Opportunities and Challenges Table 11. Attenuated Vaccine Industry Restraints Table 12. Global Attenuated Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Attenuated Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Attenuated Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Attenuated Vaccine Revenue Market Share by Region (2021-2026) Table 16. Global Attenuated Vaccine Revenue Market Share by Region (2027-2032) Table 17. Global Attenuated Vaccine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (K Units) Table 18. Global Attenuated Vaccine Sales by Region (2021-2026) & (K Units) Table 19. Global Attenuated Vaccine Sales by Region (2027-2032) & (K Units) Table 20. Global Attenuated Vaccine Sales Market Share by Region (2021-2026) Table 21. Global Attenuated Vaccine Sales Market Share by Region (2027-2032) Table 22. Global Attenuated Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Attenuated Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Attenuated Vaccine Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Attenuated Vaccine Sales Market Share by Manufacturers (2021-2026) Table 26. Global Attenuated Vaccine Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 27. Global Attenuated Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Attenuated Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Attenuated Vaccine Manufacturers, Product Type & Application Table 30. Global Attenuated Vaccine Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Attenuated Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Attenuated Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Attenuated Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Attenuated Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Attenuated Vaccine Revenue Market Share by Type (2021-2026) Table 37. Global Attenuated Vaccine Revenue Market Share by Type (2027-2032) Table 38. Global Attenuated Vaccine Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 39. Global Attenuated Vaccine Sales by Type (2021-2026) & (K Units) Table 40. Global Attenuated Vaccine Sales by Type (2027-2032) & (K Units) Table 41. Global Attenuated Vaccine Sales Market Share by Type (2021-2026) Table 42. Global Attenuated Vaccine Sales Market Share by Type (2027-2032) Table 43. Global Attenuated Vaccine Price by Type (2021-2026) & (US$/Unit) Table 44. Global Attenuated Vaccine Price by Type (2027-2032) & (US$/Unit) Table 45. Global Attenuated Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Attenuated Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Attenuated Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Attenuated Vaccine Revenue Market Share by Application (2021-2026) Table 49. Global Attenuated Vaccine Revenue Market Share by Application (2027-2032) Table 50. Global Attenuated Vaccine Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 51. Global Attenuated Vaccine Sales by Application (2021-2026) & (K Units) Table 52. Global Attenuated Vaccine Sales by Application (2027-2032) & (K Units) Table 53. Global Attenuated Vaccine Sales Market Share by Application (2021-2026) Table 54. Global Attenuated Vaccine Sales Market Share by Application (2027-2032) Table 55. Global Attenuated Vaccine Price by Application (2021-2026) & (US$/Unit) Table 56. Global Attenuated Vaccine Price by Application (2027-2032) & (US$/Unit) Table 57. Changchun BCHT Biotechnology Co.,Ltd Company Information Table 58. Changchun BCHT Biotechnology Co.,Ltd Business Overview Table 59. Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 60. Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Product Portfolio Table 61. Changchun BCHT Biotechnology Co.,Ltd Recent Development Table 62. Shanghai Rongsheng Biotech Company Information Table 63. Shanghai Rongsheng Biotech Business Overview Table 64. Shanghai Rongsheng Biotech Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 65. Shanghai Rongsheng Biotech Attenuated Vaccine Product Portfolio Table 66. Shanghai Rongsheng Biotech Recent Development Table 67. Sanofi Company Information Table 68. Sanofi Business Overview Table 69. Sanofi Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 70. Sanofi Attenuated Vaccine Product Portfolio Table 71. Sanofi Recent Development Table 72. Johnson & Johnson Company Information Table 73. Johnson & Johnson Business Overview Table 74. Johnson & Johnson Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 75. Johnson & Johnson Attenuated Vaccine Product Portfolio Table 76. Johnson & Johnson Recent Development Table 77. Merck & Co. Company Information Table 78. Merck & Co. Business Overview Table 79. Merck & Co. Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 80. Merck & Co. Attenuated Vaccine Product Portfolio Table 81. Merck & Co. Recent Development Table 82. Pfizer Inc Company Information Table 83. Pfizer Inc Business Overview Table 84. Pfizer Inc Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 85. Pfizer Inc Attenuated Vaccine Product Portfolio Table 86. Pfizer Inc Recent Development Table 87. GlaxoSmithKline plc Company Information Table 88. GlaxoSmithKline plc Business Overview Table 89. GlaxoSmithKline plc Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 90. GlaxoSmithKline plc Attenuated Vaccine Product Portfolio Table 91. GlaxoSmithKline plc Recent Development Table 92. Serum Institute of India Pvt. Ltd. Company Information Table 93. Serum Institute of India Pvt. Ltd. Business Overview Table 94. Serum Institute of India Pvt. Ltd. Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. Serum Institute of India Pvt. Ltd. Attenuated Vaccine Product Portfolio Table 96. Serum Institute of India Pvt. Ltd. Recent Development Table 97. Green Cross Corporation Company Information Table 98. Green Cross Corporation Business Overview Table 99. Green Cross Corporation Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Green Cross Corporation Attenuated Vaccine Product Portfolio Table 101. Green Cross Corporation Recent Development Table 102. CSL Limited Company Information Table 103. CSL Limited Business Overview Table 104. CSL Limited Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. CSL Limited Attenuated Vaccine Product Portfolio Table 106. CSL Limited Recent Development Table 107. Biken Company Information Table 108. Biken Business Overview Table 109. Biken Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. Biken Attenuated Vaccine Product Portfolio Table 111. Biken Recent Development Table 112. Astellas Pharma Company Information Table 113. Astellas Pharma Business Overview Table 114. Astellas Pharma Attenuated Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Astellas Pharma Attenuated Vaccine Product Portfolio Table 116. Astellas Pharma Recent Development Table 117. North America Attenuated Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 118. North America Attenuated Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 119. North America Attenuated Vaccine Sales by Type (2021-2026) & (K Units) Table 120. North America Attenuated Vaccine Sales by Type (2027-2032) & (K Units) Table 121. North America Attenuated Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 122. North America Attenuated Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 123. North America Attenuated Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 124. North America Attenuated Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 125. North America Attenuated Vaccine Sales by Application (2021-2026) & (K Units) Table 126. North America Attenuated Vaccine Sales by Application (2027-2032) & (K Units) Table 127. North America Attenuated Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 128. North America Attenuated Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 129. North America Attenuated Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 130. North America Attenuated Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 131. North America Attenuated Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 132. North America Attenuated Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 133. North America Attenuated Vaccine Sales by Country (2021-2026) & (K Units) Table 134. North America Attenuated Vaccine Sales by Country (2027-2032) & (K Units) Table 135. North America Attenuated Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 136. North America Attenuated Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 137. United States Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 138. Canada Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 139. Europe Attenuated Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 140. Europe Attenuated Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 141. Europe Attenuated Vaccine Sales by Type (2021-2026) & (K Units) Table 142. Europe Attenuated Vaccine Sales by Type (2027-2032) & (K Units) Table 143. Europe Attenuated Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 144. Europe Attenuated Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 145. Europe Attenuated Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 146. Europe Attenuated Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 147. Europe Attenuated Vaccine Sales by Application (2021-2026) & (K Units) Table 148. Europe Attenuated Vaccine Sales by Application (2027-2032) & (K Units) Table 149. Europe Attenuated Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 150. Europe Attenuated Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 151. Europe Attenuated Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 152. Europe Attenuated Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 153. Europe Attenuated Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 154. Europe Attenuated Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 155. Europe Attenuated Vaccine Sales by Country (2021-2026) & (K Units) Table 156. Europe Attenuated Vaccine Sales by Country (2027-2032) & (K Units) Table 157. Europe Attenuated Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 158. Europe Attenuated Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 159. Germany Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 160. France Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 161. U.K. Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 162. Italy Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 163. Netherlands Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 164. China Attenuated Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 165. China Attenuated Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 166. China Attenuated Vaccine Sales by Type (2021-2026) & (K Units) Table 167. China Attenuated Vaccine Sales by Type (2027-2032) & (K Units) Table 168. China Attenuated Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 169. China Attenuated Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 170. China Attenuated Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 171. China Attenuated Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 172. China Attenuated Vaccine Sales by Application (2021-2026) & (K Units) Table 173. China Attenuated Vaccine Sales by Application (2027-2032) & (K Units) Table 174. China Attenuated Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 175. China Attenuated Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 176. Asia Attenuated Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 177. Asia Attenuated Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 178. Asia Attenuated Vaccine Sales by Type (2021-2026) & (K Units) Table 179. Asia Attenuated Vaccine Sales by Type (2027-2032) & (K Units) Table 180. Asia Attenuated Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 181. Asia Attenuated Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 182. Asia Attenuated Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 183. Asia Attenuated Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 184. Asia Attenuated Vaccine Sales by Application (2021-2026) & (K Units) Table 185. Asia Attenuated Vaccine Sales by Application (2027-2032) & (K Units) Table 186. Asia Attenuated Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 187. Asia Attenuated Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 188. Asia Attenuated Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 189. Asia Attenuated Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 190. Asia Attenuated Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 191. Asia Attenuated Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 192. Asia Attenuated Vaccine Sales by Country (2021-2026) & (K Units) Table 193. Asia Attenuated Vaccine Sales by Country (2027-2032) & (K Units) Table 194. Asia Attenuated Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 195. Asia Attenuated Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 196. Japan Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 197. South Korea Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 198. India Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 199. Australia Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 200. China Taiwan Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 201. Southeast Asia Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 202. SAMEA Attenuated Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 203. SAMEA Attenuated Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 204. SAMEA Attenuated Vaccine Sales by Type (2021-2026) & (K Units) Table 205. SAMEA Attenuated Vaccine Sales by Type (2027-2032) & (K Units) Table 206. SAMEA Attenuated Vaccine Sales Price by Type (2021-2026) & (US$/Unit) Table 207. SAMEA Attenuated Vaccine Sales Price by Type (2027-2032) & (US$/Unit) Table 208. SAMEA Attenuated Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 209. SAMEA Attenuated Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 210. SAMEA Attenuated Vaccine Sales by Application (2021-2026) & (K Units) Table 211. SAMEA Attenuated Vaccine Sales by Application (2027-2032) & (K Units) Table 212. SAMEA Attenuated Vaccine Sales Price by Application (2021-2026) & (US$/Unit) Table 213. SAMEA Attenuated Vaccine Sales Price by Application (2027-2032) & (US$/Unit) Table 214. SAMEA Attenuated Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 215. SAMEA Attenuated Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 216. SAMEA Attenuated Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 217. SAMEA Attenuated Vaccine Sales by Country (2021 VS 2025 VS 2032) & (K Units) Table 218. SAMEA Attenuated Vaccine Sales by Country (2021-2026) & (K Units) Table 219. SAMEA Attenuated Vaccine Sales by Country (2027-2032) & (K Units) Table 220. SAMEA Attenuated Vaccine Sales Price by Country (2021-2026) & (US$/Unit) Table 221. SAMEA Attenuated Vaccine Sales Price by Country (2027-2032) & (US$/Unit) Table 222. Brazil Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 223. Argentina Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 224. Chile Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 225. Colombia Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 226. Peru Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 227. Saudi Arabia Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 228. Israel Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 229. UAE Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 230. Turkey Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 231. Iran Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 232. Egypt Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 233. Key Raw Materials Table 234. Raw Materials Key Suppliers Table 235. Attenuated Vaccine Distributors List Table 236. Attenuated Vaccine Customers List Table 237. Research Programs/Design for This Report Table 238. Authors List of This Report Table 239. Secondary Sources Table 240. Primary Sources List of Figures Figure 1. Attenuated Vaccine Image Figure 2. Global Attenuated Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Attenuated Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Bacterial Vaccine Image Figure 5. Viral Vaccine Image Figure 6. Global Attenuated Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Attenuated Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospital Image Figure 9. Clinic Image Figure 10. Others Image Figure 11. Global Attenuated Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Figure 13. Global Attenuated Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Attenuated Vaccine Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Attenuated Vaccine Revenue Market Share by Region (2021-2032) Figure 16. Global Attenuated Vaccine Sales (2021-2032) & (K Units) Figure 17. Global Attenuated Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 18. Global Attenuated Vaccine Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Attenuated Vaccine Sales YoY (2021-2032) & (K Units) Figure 20. Europe Attenuated Vaccine Sales YoY (2021-2032) & (K Units) Figure 21. China Attenuated Vaccine Sales YoY (2021-2032) & (K Units) Figure 22. Asia (Excluding China) Attenuated Vaccine Sales YoY (2021-2032) & (K Units) Figure 23. South America, Middle East and Africa Attenuated Vaccine Sales YoY (2021-2032) & (K Units) Figure 24. Global Attenuated Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Attenuated Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Attenuated Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Attenuated Vaccine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Attenuated Vaccine Revenue Market Share by Type (2021-2032) Figure 30. Global Attenuated Vaccine Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 31. Global Attenuated Vaccine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Attenuated Vaccine Sales Market Share by Type (2021-2032) Figure 33. Global Attenuated Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Attenuated Vaccine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Attenuated Vaccine Revenue Market Share by Application (2021-2032) Figure 36. Global Attenuated Vaccine Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 37. Global Attenuated Vaccine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Attenuated Vaccine Sales Market Share by Application (2021-2032) Figure 39. North America Attenuated Vaccine Revenue Share by Type (2021-2032) Figure 40. North America Attenuated Vaccine Sales Share by Type (2021-2032) Figure 41. North America Attenuated Vaccine Revenue Share by Application (2021-2032) Figure 42. North America Attenuated Vaccine Sales Share by Application (2021-2032) Figure 43. North America Attenuated Vaccine Revenue Share by Country (2021-2032) Figure 44. North America Attenuated Vaccine Sales Share by Country (2021-2032) Figure 45. Europe Attenuated Vaccine Revenue Share by Type (2021-2032) Figure 46. Europe Attenuated Vaccine Sales Share by Type (2021-2032) Figure 47. Europe Attenuated Vaccine Revenue Share by Application (2021-2032) Figure 48. Europe Attenuated Vaccine Sales Share by Application (2021-2032) Figure 49. Europe Attenuated Vaccine Revenue Share by Country (2021-2032) Figure 50. Europe Attenuated Vaccine Sales Share by Country (2021-2032) Figure 51. China Attenuated Vaccine Revenue Share by Type (2021-2032) Figure 52. China Attenuated Vaccine Sales Share by Type (2021-2032) Figure 53. China Attenuated Vaccine Revenue Share by Application (2021-2032) Figure 54. China Attenuated Vaccine Sales Share by Application (2021-2032) Figure 55. Asia Attenuated Vaccine Revenue Share by Type (2021-2032) Figure 56. Asia Attenuated Vaccine Sales Share by Type (2021-2032) Figure 57. Asia Attenuated Vaccine Revenue Share by Application (2021-2032) Figure 58. Asia Attenuated Vaccine Sales Share by Application (2021-2032) Figure 59. Asia Attenuated Vaccine Revenue Share by Country (2021-2032) Figure 60. Asia Attenuated Vaccine Sales Share by Country (2021-2032) Figure 61. SAMEA Attenuated Vaccine Revenue Share by Type (2021-2032) Figure 62. SAMEA Attenuated Vaccine Sales Share by Type (2021-2032) Figure 63. SAMEA Attenuated Vaccine Revenue Share by Application (2021-2032) Figure 64. SAMEA Attenuated Vaccine Sales Share by Application (2021-2032) Figure 65. SAMEA Attenuated Vaccine Revenue Share by Country (2021-2032) Figure 66. SAMEA Attenuated Vaccine Sales Share by Country (2021-2032) Figure 67. Attenuated Vaccine Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Attenuated Vaccine Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Bacterial Vaccine
  • Viral Vaccine
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Changchun BCHT Biotechnology Co.,Ltd
  • Shanghai Rongsheng Biotech
  • Sanofi
  • Johnson & Johnson
  • Merck & Co.
  • Pfizer Inc
  • GlaxoSmithKline plc
  • Serum Institute of India Pvt. Ltd.
  • Green Cross Corporation
  • CSL Limited
  • Biken
  • Astellas Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Attenuated Vaccine Market by Type
  3. 1.2.1 Global Attenuated Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Bacterial Vaccine
  5. 1.2.3 Viral Vaccine
  6. 1.3 Attenuated Vaccine Market by Application
  7. 1.3.1 Global Attenuated Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospital
  9. 1.3.3 Clinic
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Attenuated Vaccine Market Dynamics
  1. 2.1 Attenuated Vaccine Industry Trends
  2. 2.2 Attenuated Vaccine Industry Drivers
  3. 2.3 Attenuated Vaccine Industry Opportunities and Challenges
  4. 2.4 Attenuated Vaccine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Attenuated Vaccine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Attenuated Vaccine Revenue by Region
  3. 3.2.1 Global Attenuated Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Attenuated Vaccine Revenue by Region (2021-2026)
  5. 3.2.3 Global Attenuated Vaccine Revenue by Region (2027-2032)
  6. 3.2.4 Global Attenuated Vaccine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Attenuated Vaccine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Attenuated Vaccine Sales by Region
  9. 3.4.1 Global Attenuated Vaccine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Attenuated Vaccine Sales by Region (2021-2026)
  11. 3.4.3 Global Attenuated Vaccine Sales by Region (2027-2032)
  12. 3.4.4 Global Attenuated Vaccine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Attenuated Vaccine Revenue by Manufacturers
  2. 4.1.1 Global Attenuated Vaccine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Attenuated Vaccine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Attenuated Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Attenuated Vaccine Sales by Manufacturers
  6. 4.2.1 Global Attenuated Vaccine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Attenuated Vaccine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Attenuated Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Attenuated Vaccine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Attenuated Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Attenuated Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Attenuated Vaccine Manufacturers, Product Type & Application
  13. 4.7 Global Attenuated Vaccine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Attenuated Vaccine Market CR5 and HHI
  16. 4.8.2 2025 Attenuated Vaccine Tier 1, Tier 2, and Tier 3
5 Attenuated Vaccine Market by Type
  1. 5.1 Global Attenuated Vaccine Revenue by Type
  2. 5.1.1 Global Attenuated Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Attenuated Vaccine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Attenuated Vaccine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Attenuated Vaccine Sales by Type
  6. 5.2.1 Global Attenuated Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Attenuated Vaccine Sales by Type (2021-2032) & (K Units)
  8. 5.2.3 Global Attenuated Vaccine Sales Market Share by Type (2021-2032)
  9. 5.3 Global Attenuated Vaccine Price by Type
6 Attenuated Vaccine Market by Application
  1. 6.1 Global Attenuated Vaccine Revenue by Application
  2. 6.1.1 Global Attenuated Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Attenuated Vaccine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Attenuated Vaccine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Attenuated Vaccine Sales by Application
  6. 6.2.1 Global Attenuated Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Attenuated Vaccine Sales by Application (2021-2032) & (K Units)
  8. 6.2.3 Global Attenuated Vaccine Sales Market Share by Application (2021-2032)
  9. 6.3 Global Attenuated Vaccine Price by Application
7 Company Profiles
  1. 7.1 Changchun BCHT Biotechnology Co.,Ltd
  2. 7.1.1 Changchun BCHT Biotechnology Co.,Ltd Company Information
  3. 7.1.2 Changchun BCHT Biotechnology Co.,Ltd Business Overview
  4. 7.1.3 Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Product Portfolio
  6. 7.1.5 Changchun BCHT Biotechnology Co.,Ltd Recent Developments
  7. 7.2 Shanghai Rongsheng Biotech
  8. 7.2.1 Shanghai Rongsheng Biotech Company Information
  9. 7.2.2 Shanghai Rongsheng Biotech Business Overview
  10. 7.2.3 Shanghai Rongsheng Biotech Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Shanghai Rongsheng Biotech Attenuated Vaccine Product Portfolio
  12. 7.2.5 Shanghai Rongsheng Biotech Recent Developments
  13. 7.3 Sanofi
  14. 7.3.1 Sanofi Company Information
  15. 7.3.2 Sanofi Business Overview
  16. 7.3.3 Sanofi Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Attenuated Vaccine Product Portfolio
  18. 7.3.5 Sanofi Recent Developments
  19. 7.4 Johnson & Johnson
  20. 7.4.1 Johnson & Johnson Company Information
  21. 7.4.2 Johnson & Johnson Business Overview
  22. 7.4.3 Johnson & Johnson Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Johnson & Johnson Attenuated Vaccine Product Portfolio
  24. 7.4.5 Johnson & Johnson Recent Developments
  25. 7.5 Merck & Co.
  26. 7.5.1 Merck & Co. Company Information
  27. 7.5.2 Merck & Co. Business Overview
  28. 7.5.3 Merck & Co. Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Merck & Co. Attenuated Vaccine Product Portfolio
  30. 7.5.5 Merck & Co. Recent Developments
  31. 7.6 Pfizer Inc
  32. 7.6.1 Pfizer Inc Company Information
  33. 7.6.2 Pfizer Inc Business Overview
  34. 7.6.3 Pfizer Inc Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer Inc Attenuated Vaccine Product Portfolio
  36. 7.6.5 Pfizer Inc Recent Developments
  37. 7.7 GlaxoSmithKline plc
  38. 7.7.1 GlaxoSmithKline plc Company Information
  39. 7.7.2 GlaxoSmithKline plc Business Overview
  40. 7.7.3 GlaxoSmithKline plc Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 GlaxoSmithKline plc Attenuated Vaccine Product Portfolio
  42. 7.7.5 GlaxoSmithKline plc Recent Developments
  43. 7.8 Serum Institute of India Pvt. Ltd.
  44. 7.8.1 Serum Institute of India Pvt. Ltd. Company Information
  45. 7.8.2 Serum Institute of India Pvt. Ltd. Business Overview
  46. 7.8.3 Serum Institute of India Pvt. Ltd. Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Serum Institute of India Pvt. Ltd. Attenuated Vaccine Product Portfolio
  48. 7.8.5 Serum Institute of India Pvt. Ltd. Recent Developments
  49. 7.9 Green Cross Corporation
  50. 7.9.1 Green Cross Corporation Company Information
  51. 7.9.2 Green Cross Corporation Business Overview
  52. 7.9.3 Green Cross Corporation Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Green Cross Corporation Attenuated Vaccine Product Portfolio
  54. 7.9.5 Green Cross Corporation Recent Developments
  55. 7.10 CSL Limited
  56. 7.10.1 CSL Limited Company Information
  57. 7.10.2 CSL Limited Business Overview
  58. 7.10.3 CSL Limited Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 CSL Limited Attenuated Vaccine Product Portfolio
  60. 7.10.5 CSL Limited Recent Developments
  61. 7.11 Biken
  62. 7.11.1 Biken Company Information
  63. 7.11.2 Biken Business Overview
  64. 7.11.3 Biken Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 Biken Attenuated Vaccine Product Portfolio
  66. 7.11.5 Biken Recent Developments
  67. 7.12 Astellas Pharma
  68. 7.12.1 Astellas Pharma Company Information
  69. 7.12.2 Astellas Pharma Business Overview
  70. 7.12.3 Astellas Pharma Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Astellas Pharma Attenuated Vaccine Product Portfolio
  72. 7.12.5 Astellas Pharma Recent Developments
8 North America
  1. 8.1 North America Attenuated Vaccine Market Size by Type
  2. 8.1.1 North America Attenuated Vaccine Revenue by Type (2021-2032)
  3. 8.1.2 North America Attenuated Vaccine Sales by Type (2021-2032)
  4. 8.1.3 North America Attenuated Vaccine Price by Type (2021-2032)
  5. 8.2 North America Attenuated Vaccine Market Size by Application
  6. 8.2.1 North America Attenuated Vaccine Revenue by Application (2021-2032)
  7. 8.2.2 North America Attenuated Vaccine Sales by Application (2021-2032)
  8. 8.2.3 North America Attenuated Vaccine Price by Application (2021-2032)
  9. 8.3 North America Attenuated Vaccine Market Size by Country
  10. 8.3.1 North America Attenuated Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Attenuated Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Attenuated Vaccine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Attenuated Vaccine Market Size by Type
  2. 9.1.1 Europe Attenuated Vaccine Revenue by Type (2021-2032)
  3. 9.1.2 Europe Attenuated Vaccine Sales by Type (2021-2032)
  4. 9.1.3 Europe Attenuated Vaccine Price by Type (2021-2032)
  5. 9.2 Europe Attenuated Vaccine Market Size by Application
  6. 9.2.1 Europe Attenuated Vaccine Revenue by Application (2021-2032)
  7. 9.2.2 Europe Attenuated Vaccine Sales by Application (2021-2032)
  8. 9.2.3 Europe Attenuated Vaccine Price by Application (2021-2032)
  9. 9.3 Europe Attenuated Vaccine Market Size by Country
  10. 9.3.1 Europe Attenuated Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Attenuated Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Attenuated Vaccine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
10 China
  1. 10.1 China Attenuated Vaccine Market Size by Type
  2. 10.1.1 China Attenuated Vaccine Revenue by Type (2021-2032)
  3. 10.1.2 China Attenuated Vaccine Sales by Type (2021-2032)
  4. 10.1.3 China Attenuated Vaccine Price by Type (2021-2032)
  5. 10.2 China Attenuated Vaccine Market Size by Application
  6. 10.2.1 China Attenuated Vaccine Revenue by Application (2021-2032)
  7. 10.2.2 China Attenuated Vaccine Sales by Application (2021-2032)
  8. 10.2.3 China Attenuated Vaccine Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Attenuated Vaccine Market Size by Type
  2. 11.1.1 Asia Attenuated Vaccine Revenue by Type (2021-2032)
  3. 11.1.2 Asia Attenuated Vaccine Sales by Type (2021-2032)
  4. 11.1.3 Asia Attenuated Vaccine Price by Type (2021-2032)
  5. 11.2 Asia Attenuated Vaccine Market Size by Application
  6. 11.2.1 Asia Attenuated Vaccine Revenue by Application (2021-2032)
  7. 11.2.2 Asia Attenuated Vaccine Sales by Application (2021-2032)
  8. 11.2.3 Asia Attenuated Vaccine Price by Application (2021-2032)
  9. 11.3 Asia Attenuated Vaccine Market Size by Country
  10. 11.3.1 Asia Attenuated Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Attenuated Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Attenuated Vaccine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Attenuated Vaccine Market Size by Type
  2. 12.1.1 SAMEA Attenuated Vaccine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Attenuated Vaccine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Attenuated Vaccine Price by Type (2021-2032)
  5. 12.2 SAMEA Attenuated Vaccine Market Size by Application
  6. 12.2.1 SAMEA Attenuated Vaccine Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Attenuated Vaccine Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Attenuated Vaccine Price by Application (2021-2032)
  9. 12.3 SAMEA Attenuated Vaccine Market Size by Country
  10. 12.3.1 SAMEA Attenuated Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Attenuated Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Attenuated Vaccine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Attenuated Vaccine Value Chain Analysis
  2. 13.1.1 Attenuated Vaccine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Attenuated Vaccine Production Mode & Process
  6. 13.2 Attenuated Vaccine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Attenuated Vaccine Distributors
  9. 13.2.3 Attenuated Vaccine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst